Return to the catalog
Cerebrolysin
NewIn Stock60mg vial

Cerebrolysin

Neuropeptide mixture studied for brain-cell protection, communication, and recovery.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 1000.00
5+ vials — save 35%R 650.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

99%+ Purity
Extensively Researched
1

About this peptide

Cerebrolysin is a purified mixture of small peptides and amino acids derived from porcine brain tissue. Researchers use it to study how brain cells are protected, communicate, and form new connections. Studies also examine its possible role in recovery after neurological injury or age-related decline.

Why researchers reach for Cerebrolysin

Neurotrophic mimicry

Referenced across BDNF/NGF-like activity assays.

Synaptic plasticity

Preclinical data in LTP and dendritic-branching models.

Neuroprotection

Studied in ischemic and traumatic brain injury paradigms.

Key features

  • Standardized porcine neuropeptide fraction
  • Batch-verified composition
  • Endotoxin controlled
  • Cold-chain dispatch

How it works

Growth factor mimicry

Peptide fragments engage neurotrophin-like signaling.

Amyloid handling

Modulates APP processing and Aβ clearance markers in vitro.

Metabolic support

Adjusts glucose utilization in neuronal cultures.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 30 mg/mL
Reported research range5–30 mg/dayReference only

Tracking this compound? Registered researchers can log active Cerebrolysin protocols in their private Research Log.

Timing in research protocols

Once daily by infusion for 10 consecutive days.

  • Large randomised trials including CASTA and NCT00868283 used 30 mL intravenously once daily for 10 consecutive days.
  • In the stroke trials, the course was initiated within 12 hours of onset, with follow-up at 90 days.
  • Daytime infusion reflects clinical logistics rather than any demonstrated chronotherapeutic effect.
  • The studied pattern is a short intensive 10-day course, not chronic use.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Scientific name
Peptide fraction of porcine brain protein (neuropeptide preparation)
Source
Purified porcine brain fraction
Composition
~25% low-MW peptides + free amino acids
Purity
Standardized batch-to-batch
Form
Solution / lyophilized
Vial size
60 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on Cerebrolysin. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#neurotrophic#cognitive#neuroprotection

Cart (0)

Your cart is empty